Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy

Table 2

Predictive value of immunologic microenvironment and immune cells.

Variable	Patients		Agents	value for recurrence		Year/reference
		Background		Univariate	Multivariate
CD1a	59	NMIBC	BCG	0.005		2009/[27]
CD1b	59	NMIBC	BCG	<0.000		2009/[27]
CD1c	59	NMIBC	BCG	0.03		2009/[27]
CD1e	59	NMIBC	BCG	0.007		2009/[27]
MHC-1	59	NMIBC	BCG	<0.000		2009/[27]
MIG	59	NMIBC	BCG	<0.0001		2009/[27]
IP10	59	NMIBC	BCG	<0.0001		2009/[27]
TAM	66	NMIBC	BCG	0.101	0.013	2009/[28]
CD68	41	Tis	BCG	0.0002		2009/[29]
TIDC	66	NMIBC	BCG	0.210		2009/[28]
CD83	30	NMIBC	BCG	0.045	0.039	2009/[28]
Emax	38	Tis	BCG	0.01		2014/[30]
Edgn	38	Tis	BCG	0.04		2014/[30]
EAI	38	Tis	BCG	<0.004		2014/[30]
G/T ratio	38	Tis	BCG	<0.001		2014/[30]
Th2 SB	38	Tis	BCG	<0.0001		2014/[30]

BCG: Bacillus Calmette-Guérin; MHC: major histocompatibility complex; MIG: monokine induced by γ-interferon; IP10: interferon-inducible protein 10 kDa; Emax: eosinophil infiltration; TAM: tumor-associated macrophage; TIDC: tumor infiltrating dendritic cells; Edgn: eosinophil degranulation; EAI: eosinophil activity index; G/T: GATA-3⁺ lymphocytes/T-Bet⁺ lymphocytes; Th2 SB: Th2 signature biomarker.
Patients treated with more than one maintenance BCG cycle.